CX3CL1/CX3CR1 and CCL2/CCR2 chemokine/chemokine receptor complex in patients with AMD.

The chemokine receptors CX3CR1 and CCR2 have been implicated in the development of age-related macular degeneration (AMD). The evidence is mainly derived from experimental cell studies and murine models of AMD. The purpose of this study was to investigate the association between expression of CX3CR1...

Full description

Bibliographic Details
Main Authors: Mads Krüger Falk, Amardeep Singh, Carsten Faber, Mogens Holst Nissen, Thomas Hviid, Torben Lykke Sørensen
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4266494?pdf=render
_version_ 1818287613352607744
author Mads Krüger Falk
Amardeep Singh
Carsten Faber
Mogens Holst Nissen
Thomas Hviid
Torben Lykke Sørensen
author_facet Mads Krüger Falk
Amardeep Singh
Carsten Faber
Mogens Holst Nissen
Thomas Hviid
Torben Lykke Sørensen
author_sort Mads Krüger Falk
collection DOAJ
description The chemokine receptors CX3CR1 and CCR2 have been implicated in the development of age-related macular degeneration (AMD). The evidence is mainly derived from experimental cell studies and murine models of AMD. The purpose of this study was to investigate the association between expression of CX3CR1 and CCR2 on different leukocyte subsets and AMD. Furthermore we measured the plasma levels of ligands CX3CL1 and CCL2.Patients attending our department were asked to participate in the study. The diagnosis of AMD was based on clinical examination and multimodal imaging techniques. Chemokine plasma level and chemokine receptor expression were measured by flow-cytometry.A total of 150 participants were included. We found a significantly lower expression of CX3CR1 on CD8+ T cells in the neovascular AMD group compared to the control group (p = 0.04). We found a significant positive correlation between CCR2 and CX3CR1 expression on CD8+ cells (r = 0.727, p = 0.0001). We found no difference in plasma levels of CX3CL1 and CCL2 among the groups.Our results show a down regulation of CX3CR1 on CD8+ cells; this correlated to a low expression of CCR2 on CD8+ cells. Further studies are needed to elucidate the possible role of this cell type in AMD development.
first_indexed 2024-12-13T01:43:16Z
format Article
id doaj.art-a0eee61667bd45dfb2cb1b5817fcdd67
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-13T01:43:16Z
publishDate 2014-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-a0eee61667bd45dfb2cb1b5817fcdd672022-12-22T00:03:42ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01912e11247310.1371/journal.pone.0112473CX3CL1/CX3CR1 and CCL2/CCR2 chemokine/chemokine receptor complex in patients with AMD.Mads Krüger FalkAmardeep SinghCarsten FaberMogens Holst NissenThomas HviidTorben Lykke SørensenThe chemokine receptors CX3CR1 and CCR2 have been implicated in the development of age-related macular degeneration (AMD). The evidence is mainly derived from experimental cell studies and murine models of AMD. The purpose of this study was to investigate the association between expression of CX3CR1 and CCR2 on different leukocyte subsets and AMD. Furthermore we measured the plasma levels of ligands CX3CL1 and CCL2.Patients attending our department were asked to participate in the study. The diagnosis of AMD was based on clinical examination and multimodal imaging techniques. Chemokine plasma level and chemokine receptor expression were measured by flow-cytometry.A total of 150 participants were included. We found a significantly lower expression of CX3CR1 on CD8+ T cells in the neovascular AMD group compared to the control group (p = 0.04). We found a significant positive correlation between CCR2 and CX3CR1 expression on CD8+ cells (r = 0.727, p = 0.0001). We found no difference in plasma levels of CX3CL1 and CCL2 among the groups.Our results show a down regulation of CX3CR1 on CD8+ cells; this correlated to a low expression of CCR2 on CD8+ cells. Further studies are needed to elucidate the possible role of this cell type in AMD development.http://europepmc.org/articles/PMC4266494?pdf=render
spellingShingle Mads Krüger Falk
Amardeep Singh
Carsten Faber
Mogens Holst Nissen
Thomas Hviid
Torben Lykke Sørensen
CX3CL1/CX3CR1 and CCL2/CCR2 chemokine/chemokine receptor complex in patients with AMD.
PLoS ONE
title CX3CL1/CX3CR1 and CCL2/CCR2 chemokine/chemokine receptor complex in patients with AMD.
title_full CX3CL1/CX3CR1 and CCL2/CCR2 chemokine/chemokine receptor complex in patients with AMD.
title_fullStr CX3CL1/CX3CR1 and CCL2/CCR2 chemokine/chemokine receptor complex in patients with AMD.
title_full_unstemmed CX3CL1/CX3CR1 and CCL2/CCR2 chemokine/chemokine receptor complex in patients with AMD.
title_short CX3CL1/CX3CR1 and CCL2/CCR2 chemokine/chemokine receptor complex in patients with AMD.
title_sort cx3cl1 cx3cr1 and ccl2 ccr2 chemokine chemokine receptor complex in patients with amd
url http://europepmc.org/articles/PMC4266494?pdf=render
work_keys_str_mv AT madskrugerfalk cx3cl1cx3cr1andccl2ccr2chemokinechemokinereceptorcomplexinpatientswithamd
AT amardeepsingh cx3cl1cx3cr1andccl2ccr2chemokinechemokinereceptorcomplexinpatientswithamd
AT carstenfaber cx3cl1cx3cr1andccl2ccr2chemokinechemokinereceptorcomplexinpatientswithamd
AT mogensholstnissen cx3cl1cx3cr1andccl2ccr2chemokinechemokinereceptorcomplexinpatientswithamd
AT thomashviid cx3cl1cx3cr1andccl2ccr2chemokinechemokinereceptorcomplexinpatientswithamd
AT torbenlykkesørensen cx3cl1cx3cr1andccl2ccr2chemokinechemokinereceptorcomplexinpatientswithamd